GeneMatrix launches the NeoPlex COVID-19 worldwide. NeoPlex COVID-19 features high efficiency and simplicity of large-capacity testing by utilizing GeneMatrix's accumulated molecular diagnostic technology. It also reduced the testing time from 6 hours to 3 hours.
 |
Currently, there are two major methods for rapid corona diagnostic in the world, and both of them are following guidelines of the World Health Organization (WHO) and the US Centers for Disease Control and Prevention (CDC).
NeoPlex COVID-19 is designed to meet the requirements of all countries around the world by converging both WHO standards recommended by the Korea Centers for Disease Control and US CDC recommendations.
The existing COVID-19 diagnostic products had two or three tubes for testing, but the NeoPlex COVID-19 can batch test with only one tube. Besides, it verified that there was no cross-reaction with more than 50 pathogens of other respiratory infections, excluding false-positive concerns and further increasing the accuracy of the test.
